share_log

海正药业(600267.SH):环丝氨酸胶囊通过仿制药一致性评价

Haizheng Pharmaceutical (600267.SH): Cycloserine capsules passed generic drug consistency evaluation

Gelonghui Finance ·  Jan 12 04:20

Gelonghui, January 12丨Haizheng Pharmaceutical (600267.SH) announced that it has received the “Drug Supplement Application Approval Notice” for cycloserine capsules approved and issued by the State Drug Administration. The company's drug cycloserine capsules have passed the consistent evaluation of generic drug quality and efficacy. Cycloserine capsules are suitable for the treatment of active tuberculosis and extrapulmonary tuberculosis (including kidney tuberculosis) caused by tuberculosis bacteria that are sensitive to this drug and are not effective with first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethaminoethanol).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment